Moderna, Inc. (NASDAQ:MRNA) | WebDisclosure

Basculer en Français

9823	Companies
197209	Keywords
128289	Articles
104885	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 02/01/2024 at 13:00, 2 years ago

Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
Moderna, Inc. to report Q4 and full year 2023 financial results and provide corporate update in live conference call and webcast on February 22, 2024. Archived webcast available for one year

Financial Results Conference Call Moderna Inc Webcast MRNA Medicine
PRESS RELEASE

published on 01/31/2024 at 23:45, 2 years ago

Moderna Named to Fortune's List of World's Most Admired Companies
Moderna, Inc. has been recognized on Fortune's World's Most Admired Companies list, positioning among the top-50 companies. The company focuses on mRNA medicine for disease prevention and treatment, recognized for innovation and public health impact

Moderna Inc. Fortune Most Admired Companies MRNA Medicine Corporate Reputation
PRESS RELEASE

published on 01/08/2024 at 13:00, 2 years 1 month ago

Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference
Moderna, Inc. (NASDAQ: MRNA) announces impressive financial updates for 2023, with approximately $6.7 billion in product sales and an increased COVID-19 market share in the U.S. The company reiterates the expectation of approximately $4 billion in product sales for 2024, highlighting upcoming late-stage programs with anticipated milestones in 2024 and 2025. The nine late-stage programs include respiratory vaccines, next-generation COVID-19 vaccine, seasonal flu vaccine, combination vaccine against seasonal flu and COVID-19, cytomegalovirus (CMV) vaccine, individualized neoantigen therapy (INT), and rare disease therapeutics. Moderna focuses on returning to sales growth in 2025 and expects to break even in 2026 through product launches and disciplined investment. For further details, Jamey Mock will present an update on the Company and its pipeline of mRNA development programs at the 42nd Annual J.P. Morgan Healthcare Conference on January 8th, 2024, at 3:45 p.m. PT/6:45 p.m. ET.

Moderna Inc Financial Updates COVID-19 Market Share Late-stage Programs MRNA Development Programs
PRESS RELEASE

published on 12/20/2023 at 22:05, 2 years 1 month ago

Moderna to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PRESS RELEASE

published on 12/15/2023 at 00:00, 2 years 1 month ago

Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company’s Investigational Respiratory Syncytial Virus (RSV) Vaccine
PRESS RELEASE

published on 12/14/2023 at 12:30, 2 years 1 month ago

Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Comp
PRESS RELEASE

published on 12/12/2023 at 14:00, 2 years 1 month ago

Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
PRESS RELEASE

published on 12/07/2023 at 13:00, 2 years 2 months ago

Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event
PRESS RELEASE

published on 11/14/2023 at 13:00, 2 years 2 months ago

Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023
PRESS RELEASE

published on 11/08/2023 at 22:15, 2 years 3 months ago

Moderna to Present at Upcoming Conferences in November 2023

Accesswire

Published on 02/09/2026 at 15:00, 26 minutes ago

Gungnir Resources Inc. Announces Management And Board Changes
Published on 02/09/2026 at 14:15, 1 hour 11 minutes ago

White Gold Corp. Appoints Seasoned Mining Executive Donovan Pollitt as Strategic Advisor
Published on 02/09/2026 at 14:00, 1 hour 26 minutes ago

Paymetrex Secures First U.S. License Payment
Published on 02/09/2026 at 14:00, 1 hour 26 minutes ago

Geophysics Converge Ahead of Colosseum Deeper Drill Program
Published on 02/09/2026 at 13:00, 2 hours 26 minutes ago

Eagle Plains' Partner Refined Energy Corp. Mobilizes Geophysical Team to the Dufferin West Project, Saskatchewan

View all ACCESSWIRE

EQS Group

Published on 02/09/2026 at 14:52, 34 minutes ago

Aroundtown SA: Release of a capital market information
Published on 02/09/2026 at 14:20, 1 hour 6 minutes ago

EQS-Adhoc: Borussia Dortmund reports preliminary figures for the first half (H1) of the 2025/2026 financial year
Published on 02/09/2026 at 13:50, 1 hour 36 minutes ago

Cango Inc. Releases 2025 Letter to Shareholders
Published on 02/09/2026 at 13:35, 1 hour 51 minutes ago

DeFi Technologies launches the DEFT Valour Investment Opportunity Index
Published on 02/09/2026 at 13:32, 1 hour 53 minutes ago

Hapag-Lloyd publishes preliminary business figures for 2025

Les Echos

Published on 02/09/2026 at 14:49, 37 minutes ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 02/09/2026 at 10:40, 4 hours 45 minutes ago

Déclaration mensuelle du nombre total de droits de vote et du nombre d’actions composant le capital
Published on 02/09/2026 at 08:30, 6 hours 56 minutes ago

THERMADOR GROUPE : Plan to separate the roles of chairman and chief executive officer
Published on 02/09/2026 at 08:30, 6 hours 56 minutes ago

THERMADOR GROUPE : Projet de séparation des mandats de président et directeur général
Published on 02/09/2026 at 08:00, 7 hours 26 minutes ago

Eiffage renforce son expertise dans le secteur du froid industriel avec une prise de participation majoritaire dans l’entreprise française Quercy Réfrigération

View all LES ECHOS COMFI WIRE